Side-by-side comparison of AI visibility scores, market position, and capabilities
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
Israeli AI drug discovery company raised $25M from Bessemer; 40+ active programs; CEO co-patented CRISPR technology with Jennifer Doudna; ML platform combining target identification, hit generation, and lead optimization for oncology and immunology therapeutics.
Converge Bio is an Israeli AI drug discovery company using machine learning to design and optimize small molecule therapeutics across a broad portfolio of programs. Founded by a team with deep expertise in computational biology and medicinal chemistry, Converge has built a platform that combines AI-driven target identification, hit generation, and lead optimization into an integrated drug discovery engine. The company's scientific credibility is bolstered by its CEO, who co-patented CRISPR-related technology alongside Jennifer Doudna, a Nobel laureate and pioneer of gene editing.\n\nConverge operates an unusually large portfolio by biotech standards, with 40+ active drug discovery programs spanning oncology, immunology, and other therapeutic areas. The company's AI platform is designed to generate high-quality small molecule candidates faster and at lower cost than traditional medicinal chemistry approaches, enabling it to maintain a broad pipeline without the typical resource constraints of running many programs in parallel. Converge uses structure-based design, generative chemistry, and predictive ADMET modeling to advance candidates from target to preclinical candidate stage.\n\nConverge raised $25M from Bessemer Venture Partners in January 2026, bringing external validation from one of Silicon Valley's most prominent technology-focused venture firms. The funding is being used to advance lead programs toward IND filings and expand the platform's capabilities. With 40+ programs and a Nobel laureate connection in its founding story, Converge represents Israel's growing position as a global hub for AI-driven drug discovery.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.